3,4-DAA

CAT: 0804-HY-161255-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-161255-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
3,4-DAA is an orally active Anthranilic acid derivative with potent immunosuppressive activities. 3, 4-DAA can alleviate the severity of colitis through inhibiting Th1 cells response, promoting Th2 cytokines expression and inducing CD4+CD25+ T cells expression[1]. 3,4-DAA suppressed expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells induced by IFN-γ and Lipopolysaccharide[2].
CAS Number
[2117759-07-4]
UNSPSC
12352005
Target
NO Synthase
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/3-4-daa.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=C(NC(/C=C/C2=CC=C(C(OC)=C2)OC)=O)C(O)=CC=C1)O
Molecular Formula
C18H17NO6
Molecular Weight
343.33
References & Citations
[1]Quan Wen, et al. N- (3', 4'-dimethoxycinnamonyl) anthranilic acid alleviated experimental colitis by inhibiting autoimmune response and inducing CD4+ CD25+ regulatory T cells production. J Gastroenterol Hepatol. 2013 Aug;28 (8) :1330-8.|[2]Michael Platten, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005 Nov 4;310 (5749) :850-5.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products